Please try another search
As of July 22, 2014, Topotarget A/S was acquired by BioAlliance Pharma. Topotarget A/S develops and commercializes a portfolio of oncology product candidates. Its lead compound includes Belinostat (PXD101), a novel HDAC inhibitor in late-stage clinical development for the treatment of hematological malignancies and solid tumors. The company has operations in Denmark, Europe, and the United States. It has a collaboration agreement primarily with Spectrum Pharmaceuticals Inc. Topotarget A/S was founded in 2000 and is headquartered in Copenhagen, Denmark.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review